Today I want to talk about something that throws a lot of people off in their health and fitness journey: losing inches without seeing the scale move. It can feel confusing, but it’s actually more common than most people realize. You may know the feeling. You’ve been working out, eating better, maybe even taking a […]
semaglutide
Why GLP-1 Weight Loss Can Slow
Today, we’re talking about something that can be both confusing and frustrating — why weight loss can slow down on GLP-1 medications, and how other diabetes medications, like metformin or sulfonylureas, can play a role. Let’s start with the weight loss medications themselves. Semaglutide is a GLP-1 receptor agonist. It mimics the body’s natural GLP-1 […]
Fatigue on Semaglutide or Tirzepatide
If you’ve started a GLP-1 medication and found yourself thinking, “Why am I so tired all of a sudden?”, you’re definitely not alone. Today, we’re talking specifically about fatigue with semaglutide and tirzepatide—what the research actually shows, why fatigue seems more common with some GLP-1s than others, and what you can do if your energy […]
The Science Behind Semaglutide, Tirzepatide, and Retatrutide
Today we’re diving into how medications like semaglutide, tirzepatide, and retatrutide work in the body—and how they compare to the hormones your body naturally produces. Once you understand the biology behind them, their effects start to make a lot more sense. What is a peptide? Let’s start with the basics. A peptide is a molecule […]
Oral Semaglutide
Today, we’re diving into an exciting development in obesity treatment—oral semaglutide. Last week, the FDA approved Novo Nordisk’s Wegovy pill as the first and only oral GLP-1 for weight loss in adults. This approval is based on results from the OASIS-4 phase 3 clinical trial showing that a once-daily oral version of semaglutide can deliver […]
GLP-1 Therapies Strategies: Weekly, Micro-Dose, and Maintenance
Today, we’re diving into GLP‑1 therapies, including dual GIP/GLP‑1 agonists and the emerging triple agonists, and talking about how these peptides are typically dosed, what people are experimenting with, and what the research — or real-world experience — tells us so far. Most GLP‑1 receptor agonists, as well as dual and triple agonists, are designed […]